Abstract
A randomized prospective double-blind trial of CDP-Choline administration to a group of 24 preterm newborn infants with respiratory distress syndrome is reported. CDP-choline was administered by the intravenous route (100 mg/kg/day) for seven days, or until less than 30% supplemental oxygen was needed. By the fifth day of life, the patients who received CDP-choline required oxygen for a longer period of time, and had a lower lecithin/sphingomyelin ratio and palmitic acid percentage than those in the control group. At the dose given, CDP-choline did not induce postnatal pulmonary maturity. In fact, it may even decrease lecithin synthesis.
Publication types
-
Clinical Trial
-
English Abstract
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Choline / analogs & derivatives*
-
Cytidine Diphosphate Choline / therapeutic use*
-
Double-Blind Method
-
Humans
-
Infant, Newborn
-
Oxygen Inhalation Therapy
-
Palmitic Acid
-
Palmitic Acids / analysis
-
Phosphatidylcholines / analysis
-
Prospective Studies
-
Pulmonary Surfactants / analysis
-
Random Allocation
-
Respiratory Distress Syndrome, Newborn / drug therapy*
-
Respiratory Distress Syndrome, Newborn / physiopathology
-
Sphingomyelins / analysis
Substances
-
Palmitic Acids
-
Phosphatidylcholines
-
Pulmonary Surfactants
-
Sphingomyelins
-
Palmitic Acid
-
Cytidine Diphosphate Choline
-
Choline